Epigenetics Drugs Market Forecast to USD 5.8 Billion by 2020 owing to Demand for Cancer, Heart Diseases, Diabetes, and Mental Illnesses Treatment

The global epigenetics drugs market is estimated to reach USD 5.8 Billion in 2020, declining at a CAGR of 18.3% from 2016 to 2020, according to a new market research report Epigenetics Drugs Market – Global Epigenetics Drug Types and Mechanism of Action Analysis and Forecast 2013-2020, published by iHealthcareAnalyst, Inc.

Visit the Epigenetics Drugs Market – Global Epigenetics Drug Types and Mechanism of Action Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/epigenetics-drugs-market/

Epigenetics regulates gene expression in a reversible manner by chemically modifying DNA and histone proteins, which prevent permanent mutations or alterations within the genes or genome itself. Epigenetic changes beyond a normal expression pattern can cause a variety of diseases. Epigenetic therapy involves use of drugs or other epigenome-influencing techniques to treat medical conditions including cancer, heart disease, diabetes, and mental illnesses. The epigenetics drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (ChIP technology, DNA methylation), and their mechanism of action such as DNMT inhibitors - Azacitidine (vidaza) and Decitabine (dacogen); and HDAC inhibitors or HDIs - Romidepsin (istodax), Vorinostat (zolinza), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global epigenetics drugs market is segmented as:

1. Drug Type
1.1. Chromatin Immunoprecipitation (ChIP) Technology
1.2. DNA Methylation

2. Mechanism of Action
2.1. DNA Methyltransferase Inhibitors (DNMT Inhibitors)
2.1.1. Azacitidine (Vidaza)
2.1.2. Decitabine (Dacogen)
2.2. Histone Deacetylase Inhibitors (HDAC inhibitors, or HDIs)
2.2.1. Romidepsin (Istodax)
2.2.2. Vorinostat (Zolinza)

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. 4SC AG
4.2. Acetylon Pharmaceuticals, Inc.
4.3. Astex Pharmaceuticals Inc.
4.4. Celgene Corporation
4.5. Cellcentric Ltd.
4.6. Celleron Therapeutics Ltd.
4.7. Chroma Therapeutics Ltd.
4.8. Eisai Co. Ltd.
4.9. Envivo Pharmaceuticals Inc.
4.10. Epigentek Group Inc.
4.11. Epizyme, Inc.
4.12. Illumina Inc.
4.13. Mdxhealth
4.14. Merck & Company Inc.
4.15. Novartis International AG
4.16. Oncolys Biopharma Inc.
4.17. Pharmacyclics, Inc.
4.18. Promega Corporation
4.19. Repligen Corporation
4.20. Spectrum Pharmaceuticals
4.21. Syndax Pharmaceuticals, Inc.
4.22. Topotarget A/S
4.23. Valirx plc.

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com

This release was published on openPR.